Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CD38 | P28907 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 5/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | AOC1 | P19801 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2151052 | 0.90 | LMNA (0.39) | LMNAEPHX1EPHX2BCHEPTPN1 | |
| SCHEMBL2150918 | 0.90 | LMNA (0.39) | LMNAEPHX1EPHX2BCHEPTPN1 | |
| SCHEMBL25818182 | 0.90 | LMNA (0.39) | LMNAEPHX1EPHX2BCHEPTPN1 | |
| SCHEMBL2150950 | 0.88 | LMNA (0.37) | LMNAEPHX1EPHX2BCHEPTPN1 | |
| SCHEMBL2150952 | 0.87 | LMNA (0.38) | LMNAEPHX1EPHX2BCHEPTPN1 | |
| SCHEMBL2151012 | 0.87 | LMNA (0.38) | LMNAEPHX1EPHX2BCHEPTPN1 | |
| SCHEMBL28043235 | 0.85 | LMNA (0.39) | LMNAEPHX1EPHX2BCHEPTPN1 | |
| SCHEMBL2151155 | 0.85 | LMNA (0.43) | LMNAEPHX1EPHX2CD38BCHE | |
| SCHEMBL15576263 | 0.84 | LMNA (0.41) | LMNAEPHX1EPHX2BCHEPTPN1 | |
| SCHEMBL15461617 | 0.84 | LMNA (0.41) | LMNAEPHX1EPHX2BCHEPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | PNMT 2114/4885LMNA 566/4885EPHX1 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.